Dilikoglu ResearchIDEAS. ANALYSIS. PERSPECTIVE.Scenario assumptions follow each company’s operating model and disclosed economics. Forecasts, priors, financing assumptions and valuation inputs are Dilikoglu Research estimates.
Consistent scenario definitions and underwriting discipline, with company-specific probabilities based on evidence and risk. The evidence hierarchy and downside discipline are standardized; identical probabilities and identical economics are not required.
ARR/MW, ACV/MW, NOI/MW, utilization, capex/MW, financing and customer economics are company-specific and evidence-driven. Process is standardized; economic assumptions are not.
Primary filings and contractual terms take priority over company presentations, management commentary and third-party context. DR estimates remain separately labeled. New initiations use a Base-case target and the published ±15% rating convention, subject to an explicit analyst review of downside. Historical report exceptions remain identified. Live prices and interactive diagnostics do not automatically change a published rating. See the rating and target methodology.
| Company | Failure | Bear | Base | Bull |
|---|---|---|---|---|
| IREN | 10% | 25% | 45% | 20% |
| NBIS | 10% | 30% | 45% | 15% |
| CRWV | 10% | 30% | 45% | 15% |
| CIFR | 10% | 25% | 45% | 20% |
| HUT | 10% | 25% | 45% | 20% |
| WULF | 10% | 25% | 45% | 20% |
| MU | 10% | 25% | 45% | 20% |
| COHR | 10% | 25% | 45% | 20% |
| NVDA | 10% | 25% | 45% | 20% |
| AMD | 10% | 25% | 45% | 20% |
| AEHR | 10% | 25% | 45% | 20% |
| AVGO | 10% | 25% | 45% | 20% |
| LITE | 10% | 25% | 45% | 20% |
| SKHY | 10% | 25% | 45% | 20% |
| TSM | 10% | 25% | 45% | 20% |
| AAOI | 10% | 25% | 45% | 20% |
Failure represents capital loss or a broken investment case; Bear represents material disappointment; Base is the central research case; Bull represents a strong but plausible outcome. Scenario weights are analyst priors, not empirically calibrated frequencies. Scenario weights are separate from simulated outcome probabilities. Review the company Coverage page for scenario mechanisms and weighted-value contributions.
Only a published report assigns a formal recommendation. The standard convention for new initiation reports is a Base-case target over 12–18 months, with probability-weighted value and the simulation median shown separately. Above +15% target upside is BUY, below −15% is SELL, otherwise HOLD, measured against the dated report reference. Upside uses the published rounded target, not the unrounded Base value.
Targets round to the nearest $5 at $50 or above and the nearest $1 below $50. A departure from this convention requires an explicit explanation in the report. Existing reports retain their original conventions: IREN uses probability-weighted value; IREN and NBIS retain their report-specific recommendation judgments. These exceptions are historical, not changes to the current model.
A threshold is a starting convention, not a substitute for downside review. Every new recommendation must discuss scenario losses, financing, dilution, evidence quality and upside-tail dependence. If PW or the simulation median is below the dated reference, a BUY requires a written investment justification. Model updates do not automatically change a published rating; a formal recommendation change requires a dated research update.
PW = sum of scenario weight × scenario value. Weights and Monte Carlo distributions are analyst judgments, not empirically calibrated probabilities. Neither PW nor the simulation median should be described as a verified expected market return.
| Company | Publication status | Target framework |
|---|---|---|
| IREN | Published Coverage · 2026-09-13 | Probability-weighted intrinsic value of $98.91, rounded to $100. The report uses the scenario-weighted outcome to reflect execution and financing risk. Report → |
| NBIS | Published Coverage · 2026-09-20 | Base intrinsic value of $265.43, rounded to the nearest $5. This is a Base-case realization target, not an expected-return target. Probability-weighted value is $215.89, below the $223.54 report reference; BUY does not imply positive probability-weighted upside. Report → |
| CRWV | Published Coverage · 2026-09-26 | Base DCF $124.04 rounded to $125. PW $151.60 and ARR cross-check $168.56 are separate measures. The 50% future-sales allocation is a DR estimate. Report → |
| CIFR | Published Coverage · 2026-10-05 | Base intrinsic value $16.24 rounded to $16. Probability-weighted value $12.46 and finite-lease DCF $8.49 are separate measures. Report → |
| HUT | Model Preview / Research in Progress | No formal published recommendation or target. |
| WULF | Model Preview / Research in Progress | No formal published recommendation or target. |
| MU | Model Preview / Research in Progress | No formal published recommendation or target. |
| COHR | Model Preview / Research in Progress | No formal published recommendation or target. |
| NVDA | Published Coverage · 2026-10-08 | Base intrinsic value $302.15 rounded to $300. Probability-weighted value $308.02 is a separate scenario measure. Report → |
| AMD | Published Coverage · 2026-10-18 | Base intrinsic value $607.56 rounded to the nearest $5. The $610 target implies 15.4% upside; unrounded Base upside is 14.9%. Probability-weighted value is $591.16; simulation median $484.44 is below the reference. BUY is a high-risk, Base-led judgment. Report → |
| AEHR | Model Preview / Research in Progress | No formal published recommendation or target. |
| AVGO | Model Preview / Research in Progress | No formal published recommendation or target. |
| LITE | Model Preview / Research in Progress | No formal published recommendation or target. |
| SKHY | Model Preview / Research in Progress | No formal published recommendation or target. |
| TSM | Model Preview / Research in Progress | No formal published recommendation or target. |
| AAOI | Model Preview / Research in Progress | No formal published recommendation or target. |
| Company | Primary KPI | Valuation method |
|---|---|---|
| IREN | AI-cloud ARR / IT MW | EV/ARR + residual power value |
| NBIS | YE27 ARR / commercial MW | AI Cloud EV/YE27 ARR + non-core SOTP − economic net debt |
| CRWV | ARR / active MW | Replacement-aware DCF; EV/ARR cross-check |
| CIFR | Lease NOI / critical IT MW | Blended stabilized-NOI SOTP; DCF cross-check |
| HUT | Project NOI / contracted IT MW | Project NAV + risked pipeline option |
| WULF | Lease NOI / contracted IT MW | Project NAV + risked powered-land option |
| MU | Bit volume × ASP; normalized cash returns | FY27–FY36 FCFF DCF plus normalized earnings sensitivity |
| COHR | Delivered product volume × selling price; cash conversion | FY27–FY36 discounted FCFF plus scenario exit EV/EBIT; perpetuity FCFF cross-check |
| NVDA | Customer-group revenue growth, operating margin and cash conversion | H2 FY27–FY36 FCFF DCF with a gradual terminal transition; exit EV/EBIT cross-check |
| AMD | Instinct ramp, EPYC growth, operating leverage and cash conversion | H2 2026–FY2035 FCFF DCF; conditional warrants; exit EV/EBIT cross-check |
| AEHR | Backlog conversion, consumables demand and cash conversion | Remaining FY2027–FY2036 cash flows plus exit EV/EBIT; finite awards / tax shield; perpetuity FCFF cross-check |
| AVGO | AI outlook execution and cash conversion | Q4 FY2026–FY2035 FCFF DCF; AMD discount conventions; exit EV/EBIT cross-check |
| LITE | FY2028 outlook delivery and cash conversion | FY2027–36 FCFF plus discounted exit EV/EBIT; perpetuity cross-check |
| SKHY | Memory bit growth, selling prices and cash returns | FY2027–2036 FCFF DCF; normalized earnings cross-check |
| TSM | HPC delivery, operating margin and cash return on fab investment | Remaining 2026 + FY2027–2036 FCFF DCF; EV/EBIT cross-check |
| AAOI | 800G / 1.6T delivery and cash conversion | Remaining 2026 and FY2027–36 FCFF plus discounted exit EV/EBIT; perpetuity cross-check |
Company source registers distinguish reported information, management commentary and DR estimates. Recovered inputs and unfinished primary-source verification are disclosed; no universal readiness percentages are imposed on the reconstructed models.
← Portfolio Analytics · IREN model · NBIS · CIFR · CRWV · HUT · WULF · MU · COHR · NVDA · AMD · AVGO model · LITE model · SKHY model · AAOI model · TSM model · AEHR